Access the full text.
Sign up today, get DeepDyve free for 14 days.
Allan Li, D. Chitale, Gregory Riely, W. Pao, V. Miller, M. Zakowski, V. Rusch, M. Kris, M. Ladanyi (2008)EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.
The Journal of molecular diagnostics : JMD, 10 3
E. Massarelli, M. Varella-Garcia, Ximing Tang, A. Xavier, N. Ozburn, Diane Liu, B. Bekele, R. Herbst, I. Wistuba (2007)KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer
Clinical Cancer Research, 13
T. Lynch, D. Bell, Raffaella Sordella, S. Gurubhagavatula, R. Okimoto, Brian Brannigan, Patricia Harris, Sara Haserlat, J. Supko, F. Haluska, D. Louis, D. Christiani, J. Settleman, D. Haber (2004)Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
The New England journal of medicine, 350 21
Mok (2009)Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
N Engl J Med, 361
D. Eberhard, B. Johnson, L. Amler, A. Goddard, Sherry Heldens, R. Herbst, William Ince, P. Jänne, T. Januario, David Johnson, P. Klein, V. Miller, M. Ostland, D. Ramies, Dragan Sebisanovic, Jeremy Stinson, Yu Zhang, S. Seshagiri, K. Hillan (2005)Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 25
(1996)RAS oncogenes and human lung cancer
W. Pao, Theresa Wang, Gregory Riely, V. Miller, Qiulu Pan, M. Ladanyi, M. Zakowski, R. Heelan, M. Kris, H. Varmus (2005)KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
PLoS Medicine, 2
Qiulu Pan, W. Pao, M. Ladanyi (2005)Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.
The Journal of molecular diagnostics : JMD, 7 3
Donghui Li, Jeffrey Morris, Jun Liu, Manal Hassan, R. Day, Melissa Bondy, J. Abbruzzese (2009)F1000 highlights
Asia‐Pacific Journal of Clinical Oncology, 5
R. Leidner, P. Fu, B. Clifford, A. Hamdan, C. Jin, R. Eisenberg, T. Boggon, M. Skokan, W. Franklin, F. Cappuzzo, F. Hirsch, M. Varella-Garcia, B. Halmos (2009)Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 33
J. Paez, P. Jänne, Jeffrey Lee, Sean Tracy, H. Greulich, S. Gabriel, P. Herman, F. Kaye, N. Lindeman, T. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. Eck, W. Sellers, B. Johnson, M. Meyerson (2004)EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Gregory Riely, M. Kris, D. Rosenbaum, J. Marks, Allan Li, D. Chitale, K. Nafa, E. Riedel, M. Hsu, W. Pao, V. Miller, M. Ladanyi (2008)Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma
Clinical Cancer Research, 14
A. Tsao, X. Tang, B. Sabloff, Lianchun Xiao, H. Shigematsu, J. Roth, M. Spitz, W. Hong, A. Gazdar, I. Wistuba (2006)Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer
Journal of Thoracic Oncology, 1
S. Yang, Leah Mechanic, Ping Yang, M. Landi, E. Bowman, J. Wampfler, D. Meerzaman, Kyeong-Man Hong, Felicia Mann, T. Dracheva, J. Fukuoka, W. Travis, N. Caporaso, C. Harris, J. Jen (2005)Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer
Clinical Cancer Research, 11
W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, Bhuvanesh Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, Doris Kupfer, R. Wilson, M. Kris, H. Varmus (2004)EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
Proceedings of the National Academy of Sciences of the United States of America, 101 36
S. Krishnaswamy, R. Kanteti, J. Duke-Cohan, Sivakumar Loganathan, Wanqing Liu, P. Ma, M. Sattler, P. Singleton, N. Ramnath, F. Innocenti, D. Nicolae, Ouyang Zheng, Jie Liang, J. Minna, M. Kozloff, M. Ferguson, V. Natarajan, Yi-Ching Wang, Joe Garcia, E. Vokes, R. Salgia (2009)Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer
Clinical Cancer Research, 15
E. Calvo, J. Baselga (2006)Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 14
J. Hunt, A. Strimas, Julie Martin, Marilyn Eyer, M. Haddican, Brian Luckett, B. Ruiz, T. Axelrad, W. Backes, E. Fontham (2002)Differences in KRAS mutation spectrum in lung cancer cases between African Americans and Caucasians after occupational or environmental exposure to known carcinogens.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 11 11
A. Jemal, R. Siegel, Elizabeth Ward, Y. Hao, Jiaquan Xu, M. Thun (2009)Cancer Statistics, 2009
CA: A Cancer Journal for Clinicians, 59
N. Dubrawsky (1989)Cancer statistics
CA: A Cancer Journal for Clinicians, 39
Gregory Riely, W. Pao, Duykhanh Pham, Allan Li, N. Rizvi, E. Venkatraman, M. Zakowski, M. Kris, M. Ladanyi, V. Miller (2006)Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
Clinical Cancer Research, 12
ORIGINAL ARTICLE Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans J. Matthew Reinersman, MD,* Melissa L. Johnson, MD,† Gregory J. Riely, MD, PhD,† Dhananjay A. Chitale, MD,* Anthony D. Nicastri, MD,‡ Gerald A. Soff, MD,** Ann G. Schwartz, MD,§ Camelia S. Sima, MD, MS, Getinet Ayalew, MD,‡ Christopher Lau, PhD,¶ Maureen F. Zakowski, MD,¶ Valerie W. Rusch, MD,# Marc Ladanyi, MD,*¶ and Mark G. Kris, MD† 0.11). KRAS mutations were more likely among whites, 26% (125/ Introduction: The detection of mutations in the epidermal growth 476, 95% CI: 23–30%; p 0.04). factor receptor (EGFR) gene, which predict sensitivity to treatment Conclusions: This is the largest study to date examining the fre- with EGFR tyrosine kinase inhibitors, represents a major advance in quency of mutations in lung adenocarcinomas in African Americans. the treatment of lung adenocarcinoma. KRAS mutations confer Although KRAS mutations were somewhat less likely, there was no resistance to EGFR-tyrosine kinase inhibitors. The prevalence of difference between the frequencies of EGFR mutations in African these mutations in African American patients has not been thor- American patients, when compared with whites. These results sug- oughly investigated. gest that all patients with advanced lung adenocarcinomas
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: Jan 1, 2011
Access the full text.
Sign up today, get DeepDyve free for 14 days.